Condition
Relapsed Acute Myeloid Leukemia (AML)
Total Trials
3
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Not Yet Recruiting1
Active Not Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06846606Phase 1Active Not RecruitingPrimary
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
NCT07347418Phase 1Not Yet Recruiting
CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML or HR-MDS
NCT03787498Phase 1CompletedPrimary
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Showing all 3 trials